InterCure Ltd., including its subsidiaries, is actively involved in the entire lifecycle of medical cannabis products. This encompasses everything from initial research ...
InterCure Ltd. (NASDAQ: INCR) is described as a vertically integrated pharmaceutical cannabis company operating across the full lifecycle of medical cannabis products—from early-stage research and cultivation through manufacturing and global distribution. The company’s core offering includes pharmaceutical-grade dried cannabis flower and cannabis extracts infused with oil, positioned for use as ...InterCure Ltd. (NASDAQ: INCR) is described as a vertically integrated pharmaceutical cannabis company operating across the full lifecycle of medical cannabis products—from early-stage research and cultivation through manufacturing and global distribution. The company’s core offering includes pharmaceutical-grade dried cannabis flower and cannabis extracts infused with oil, positioned for use as clinical-quality products. In addition to its cannabis operations, InterCure also directs investment activity toward the biomedical sector, reflecting a broader healthcare orientation beyond cannabis alone.
From a business-model perspective, InterCure’s value proposition centers on control of multiple steps of the supply chain: DNA/research activities, cultivation, production/manufacturing, and downstream commercialization/distribution. That integration is intended to support consistent product quality, operational execution, and the ability to serve both domestic and international markets. The company is also referenced as providing patient-facing access through dedicated pharmacies in Israel and Germany, which aligns with a patient-treatment pathway rather than a purely wholesale model.
Product-wise, the company’s cannabis portfolio focuses on dried flower and standardized extract formats (including oil-infused extracts). These product types are commonly used in medical treatment regimens and can require controlled production and regulatory-compliant handling. The company’s activities therefore span manufacturing processes, marketing/commercialization, and distribution logistics, supported by its in-house or subsidiary capabilities.
Operationally, the provided financial dataset includes metrics such as current ratio (1.478), but also shows negative profitability measures on a trailing-twelve-month basis (e.g., negative net profit margin and EBIT/EBITDA margins). This suggests the company has faced cost/expense pressures, potentially associated with growth investments, regulatory/compliance costs, capacity ramp-ups, and/or R&D and commercialization activities typical for specialized healthcare manufacturing businesses.
In terms of scale, workforce data provided indicates a headcount around the mid-hundreds (about 285 employees as of 2025–2026 intelligence reporting), placing InterCure in the 201–500 employee band. Leadership is attributed to Alexander Rabinovich, who is listed as Founder & Chief Executive Officer, indicating continuity in management and strategy.
Overall, InterCure aims to be a leading pharmaceutical cannabis provider outside the United States, combining supply-chain integration with patient access mechanisms and parallel biomedical investment initiatives. Key stakeholders include executive management (Alexander Rabinovich) and other senior roles such as CFO (Amos Cohen) as referenced in the provided executive-team information.
YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.
QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).
$270.2M
+13.1%
0.0%
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.
$-35.7M
+47.3%
0.0%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.
+12.3%
-3.0%
0.0%
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).
+2.5%
+108.9%
0.0%
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.
-13.2%
+53.4%
0.0%
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.
$13.3M
+118.6%
+512.7%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.
+4.9%
+116.5%
+512.7%
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.
46.2%
-13.3%
0.0%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.
1.48x
-14.5%
0.0%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.
